What is Jade Biosciences, Inc.'s (JBIO) StockRank?

MoatMap's StockRank for Jade Biosciences, Inc. (JBIO) is 34/100, with a Sell signal. This is a composite score combining Quality (44), Value (28), and Momentum (54) factor ranks across MoatMap's 20,000+ stock universe.

Does Jade Biosciences, Inc. have an economic moat?

Jade Biosciences, Inc. (JBIO) has a Quality factor score of 44/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Jade Biosciences, Inc. a buy, hold, or sell?

MoatMap's current signal for Jade Biosciences, Inc. (JBIO) is Sell, based on a StockRank of 34/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Jade Biosciences, Inc. in?

Jade Biosciences, Inc. (JBIO) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

JBIO

SELLREMOVE

Jade Biosciences, Inc. · Healthcare · United States · $1.0B · Avg Vol: $18M/d

StockRank

P/E (TTM)

—

ROE

—

D/E

0.0x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Jade Biosciences is a pre-revenue biotechnology firm that does not meet our criteria for established quality compounders with high ROIC and pricing power.

COMPANY DESCRIPTION

Jade Biosciences, Inc. is a clinical-stage biotechnology company focused on developing novel treatments for various medical conditions. Its therapeutic approach aims to address unmet medical needs, providing potential for significant market impact if successful. The company is a research-driven biotech enterprise seeking to bring innovative therapies to market.

FINANCIAL SUMMARY (USD)

Year	2025
Revenue	0
EPS	-3.19
Shares	49.3M
Debt	0.7M
Equity	332.5M
Op CF	-94.7M
Inv CF	-247.0M
Fin CF	360.8M

PRICE (1Y)-30.6%

SMA 50SMA 200

$16.82

RSI (14)

30.7

52W High

$28.00

From 52W High

0.6%

SCORE BREAKDOWN

Quality

ROIC

-34.1%19.8

ROE

—N/A

GP/Assets

—N/A

Op. Margin

0.0%40.4

FCF/Assets

—N/A

Piotroski

239.0

Int. Cover

—N/A

D/E Ratio

0.00x95.1

Current Ratio

14.29x92.1

Value

P/E (TTM)

—N/A

EV/EBITDA

—N/A

P/FCF

—N/A

P/B

2.6x45.8

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

60%40.1

RS 6M

-6%72.2

SMA 50/200

1.45x97.6

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$1.0B

P/E (Forward)

—

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of JBIO are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
JBIO	Jade Biosciences, Inc.(you)	$1.0B	34	SELL
CRVS	Corvus Pharmaceuticals, Inc.	$1.1B	33	SELL
MNKD	MannKind Corporation	$1.1B	31	SELL
PHAT	Phathom Pharmaceuticals, Inc.	$823M	33	SELL
SVRA	Savara Inc.	$1.0B	27	SELL
LBRX	LB Pharmaceuticals Inc	$789M	32	SELL
ANL	Adlai Nortye Ltd.	$728M	35	HOLD
ANNX	Annexon, Inc.	$880M	28	SELL
GLUE	Monte Rosa Therapeutics, Inc.	$1.6B	34	SELL
ABSI	Absci Corporation	$948M	42	HOLD

Peer medians: ROE -22.6% · P/E 25.3x · Gross margin 44.3%

Jade Biosciences, Inc. (JBIO) — Stock Score Summary

Jade Biosciences, Inc. (JBIO) has a MoatMap StockRank of 34/100 based on Quality (44/100), Value (28/100), and Momentum (54/100) factor scores. The current signal is SELL. Jade Biosciences is a pre-revenue biotechnology firm that does not meet our criteria for established quality compounders with high ROIC and pricing power.

Key Financial Metrics

Price	$16.82
Market Cap	$1.0B
Price/Book	2.55
Return on Invested Capital	-34.1%
Debt/Equity	0.29
Gross Margin	0.0%
Operating Margin	0.0%

Jade Biosciences, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Jade Biosciences, Inc.’s (JBIO) StockRank?: MoatMap’s StockRank for Jade Biosciences, Inc. (JBIO) is 34/100, with a Sell signal. It is a composite of Quality (44), Value (28), and Momentum (54) factor ranks across MoatMap’s 20,000+ stock universe.
Does Jade Biosciences, Inc. have an economic moat?: Jade Biosciences, Inc. (JBIO) has a Quality factor score of 44/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Jade Biosciences, Inc. a buy, hold, or sell?: MoatMap’s current signal for Jade Biosciences, Inc. (JBIO) is Sell, based on a StockRank of 34/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Jade Biosciences, Inc. in?: Jade Biosciences, Inc. (JBIO) operates in the Healthcare sector, specifically the Biotechnology industry (United States).